

NOV 20 2000



TECH CENTER 1600/2200

Patent Docket P1101P1

UNITED STATES PATENT AND TRADEMARK OFFICE

| | |
|---|--|
| <p>In re Application of Ashkenazi et al. Serial No.: 09/020,746 Filed: February 9, 1998 For: Apo-2 Receptor</p> | <p>Group Art Unit: 1646 Examiner: L. Spector</p> <hr/> <p>CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231 on November 9, 2000 <i>Diane L. Marschang</i> Diane L. Marschang</p> |
|---|--|

C/22
11/21/00
(W.E.)
ok
to enter
11/30/00
[Signature]

AMENDMENT

Box AF
Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:

This paper is being filed in response to the Office Action mailed May 12, 2000. Entry of the following amendments and consideration of the remarks herein are respectfully requested.

IN THE CLAIMS:

Please cancel claims 19 and 20 without prejudice.

21. (Amended) A monoclonal antibody which (a) binds to Apo-2 polypeptide [comprising] consisting of the contiguous amino acid residues 1 to 411 of SEQ ID NO:1 and (b) stimulates apoptosis in at least one type of mammalian cell in vivo or ex vivo.

e 1 4A
22. (Amended) A monoclonal antibody which (a) binds to a soluble [polypeptide comprising an] extracellular domain sequence of an [native sequence] Apo-2 polypeptide which [comprises] consists of amino acids 54 to 182 of SEQ ID NO:1 and (b) stimulates apoptosis in at least one type

85

C